Trial Outcomes & Findings for Lapatinib in Combination With Vinorelbine (NCT NCT01128543)

NCT ID: NCT01128543

Last Updated: 2012-12-12

Results Overview

Par. with CB are defined as those with complete response (CR), partial response (PR), or stable disease (SD) for \>=12 or 24 weeks. Per Response Evaluation Criteria In Solid Tumors (RECIST), Version 1.1, CR is defined as the disappearance of all target lesions, PR is defined as a \>=30% decrease in the sum of the longest diameter (LD) of target lesions, taking as a reference the baseline sum LD, and SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as a reference the smallest sum LD since the treatment started.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

29 participants

Primary outcome timeframe

Week 12 and Week 24

Results posted on

2012-12-12

Participant Flow

Participant milestones

Participant milestones
Measure
Lapatinib 1250 mg and Vinorelbine 20 mg/m^2
Participants received 1250 milligram (mg) tablets lapatinib once a day and vinorelbine 20 mg/meters squared (m\^2) intravenously on Day 1 and Day 8, and every 3 weeks.
Overall Study
STARTED
29
Overall Study
COMPLETED
25
Overall Study
NOT COMPLETED
4

Reasons for withdrawal

Reasons for withdrawal
Measure
Lapatinib 1250 mg and Vinorelbine 20 mg/m^2
Participants received 1250 milligram (mg) tablets lapatinib once a day and vinorelbine 20 mg/meters squared (m\^2) intravenously on Day 1 and Day 8, and every 3 weeks.
Overall Study
Withdrawal by Subject
3
Overall Study
Protocol Violation
1

Baseline Characteristics

Lapatinib in Combination With Vinorelbine

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Lapatinib 1250 mg and Vinorelbine 20 mg/m^2
n=29 Participants
Participants received 1250 milligram (mg) tablets lapatinib once a day and vinorelbine 20 mg/meters squared (m\^2) intravenously on Day 1 and Day 8, and every 3 weeks.
Age Continuous
54 Years
STANDARD_DEVIATION 13.2 • n=5 Participants
Sex: Female, Male
Female
29 Participants
n=5 Participants
Sex: Female, Male
Male
0 Participants
n=5 Participants
Race/Ethnicity, Customized
Caucasian
29 participants
n=5 Participants

PRIMARY outcome

Timeframe: Week 12 and Week 24

Population: All participants randomized to receive at least one dose of study drug. Of the 29 participants enrolled in the study, 25 were evaluable for analysis; 4 participants withdrew from the study.

Par. with CB are defined as those with complete response (CR), partial response (PR), or stable disease (SD) for \>=12 or 24 weeks. Per Response Evaluation Criteria In Solid Tumors (RECIST), Version 1.1, CR is defined as the disappearance of all target lesions, PR is defined as a \>=30% decrease in the sum of the longest diameter (LD) of target lesions, taking as a reference the baseline sum LD, and SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as a reference the smallest sum LD since the treatment started.

Outcome measures

Outcome measures
Measure
Lapatinib 1250 mg and Vinorelbine 20 mg/m^2
n=25 Participants
Participants received 1250 milligram (mg) tablets lapatinib once a day and vinorelbine 20 mg/meters squared (m\^2) intravenously on Day 1 and Day 8, and every 3 weeks.
Number of Participants (Par.) With Clinical Benefit (CB) at Week 12 and Week 24
Week 12, CR
0 participants
Number of Participants (Par.) With Clinical Benefit (CB) at Week 12 and Week 24
Week 12, PR
4 participants
Number of Participants (Par.) With Clinical Benefit (CB) at Week 12 and Week 24
Week 12, SD
12 participants
Number of Participants (Par.) With Clinical Benefit (CB) at Week 12 and Week 24
Week 24, CR
0 participants
Number of Participants (Par.) With Clinical Benefit (CB) at Week 12 and Week 24
Week 24, PR
4 participants
Number of Participants (Par.) With Clinical Benefit (CB) at Week 12 and Week 24
Week 24, SD
10 participants

SECONDARY outcome

Timeframe: From the start of treatment until disease progression, death, or discontinuation from the study (average of 102.7 months)

Population: All participants randomized to receive at least one dose of study drug. Of the 29 participants enrolled in the study, 25 were evaluable for analysis; 4 participants withdrew from the study.

Per RECIST, Version 1.1, Progressive Disease is defined as at least a 20% increase in the sum of the LD of target lesions, taking as a reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

Outcome measures

Outcome measures
Measure
Lapatinib 1250 mg and Vinorelbine 20 mg/m^2
n=25 Participants
Participants received 1250 milligram (mg) tablets lapatinib once a day and vinorelbine 20 mg/meters squared (m\^2) intravenously on Day 1 and Day 8, and every 3 weeks.
Progression-free Survival
87.7 months
Standard Deviation 8.7

SECONDARY outcome

Timeframe: From the start of treatment until a complete response or partial response was reached (up to Week 90; average of 21.3 weeks)

Population: All participants randomized to receive at least one dose of study drug. Only those participants with a complete or partial response were evaluated.

Duration of response was measured in participants who experienced either a complete response or a partial response. Per RECIST, Version 1.1, complete response is defined as the disappearance of all target lesions, and partial response is defined as a \>=30% decrease in the sum of the longest diameter of target lesions, taking as a reference the baseline sum longest diameter.

Outcome measures

Outcome measures
Measure
Lapatinib 1250 mg and Vinorelbine 20 mg/m^2
n=19 Participants
Participants received 1250 milligram (mg) tablets lapatinib once a day and vinorelbine 20 mg/meters squared (m\^2) intravenously on Day 1 and Day 8, and every 3 weeks.
Duration of Response
4.6 months
Interval 4.0 to 8.0

Adverse Events

Lapatinib 1250 mg and Vinorelbine 20 mg/m^2

Serious events: 8 serious events
Other events: 27 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Lapatinib 1250 mg and Vinorelbine 20 mg/m^2
n=29 participants at risk
Participants received 1250 milligram (mg) tablets lapatinib once a day and vinorelbine 20 mg/meters squared (m\^2) intravenously on Day 1 and Day 8, and every 3 weeks.
Blood and lymphatic system disorders
Febrile neutropenia
3.4%
1/29
Respiratory, thoracic and mediastinal disorders
Pneumonia
3.4%
1/29
Infections and infestations
Candida sepsis
3.4%
1/29
Renal and urinary disorders
Urinary infection
3.4%
1/29
Blood and lymphatic system disorders
Lymphopenia
3.4%
1/29
Gastrointestinal disorders
Vomiting
3.4%
1/29
Blood and lymphatic system disorders
Lymphangitis
3.4%
1/29
Nervous system disorders
Motor deficit
3.4%
1/29
Gastrointestinal disorders
Abdominal epigastric pain
3.4%
1/29
Gastrointestinal disorders
Diarrhea
10.3%
3/29

Other adverse events

Other adverse events
Measure
Lapatinib 1250 mg and Vinorelbine 20 mg/m^2
n=29 participants at risk
Participants received 1250 milligram (mg) tablets lapatinib once a day and vinorelbine 20 mg/meters squared (m\^2) intravenously on Day 1 and Day 8, and every 3 weeks.
Blood and lymphatic system disorders
Neutropenia
62.1%
18/29
Blood and lymphatic system disorders
Leucopenia
55.2%
16/29
Gastrointestinal disorders
Diarrhea
48.3%
14/29
General disorders
Loss of appetite
48.3%
14/29
Blood and lymphatic system disorders
Anemia
37.9%
11/29
Gastrointestinal disorders
Vomiting
37.9%
11/29
General disorders
Fatigue
37.9%
11/29
Investigations
High alanine transaminase
31.0%
9/29
Investigations
High aspartate transaminase
31.0%
9/29
Respiratory, thoracic and mediastinal disorders
Mucositis
31.0%
9/29
Skin and subcutaneous tissue disorders
Eruption
24.1%
7/29
Musculoskeletal and connective tissue disorders
Pain
20.7%
6/29
Gastrointestinal disorders
Constipation
24.1%
7/29
Gastrointestinal disorders
Abdominal pain
13.8%
4/29
Nervous system disorders
Change in taste
13.8%
4/29
Investigations
High alkaline phosphatase
10.3%
3/29
General disorders
Fever
10.3%
3/29
Skin and subcutaneous tissue disorders
Skin toxicity
10.3%
3/29
General disorders
Reaction on injection region
10.3%
3/29
Hepatobiliary disorders
Hepatotoxicity
10.3%
3/29
Infections and infestations
Urinary system infection
10.3%
3/29
Gastrointestinal disorders
Stomatitis
6.9%
2/29
Immune system disorders
Allergy
6.9%
2/29
Nervous system disorders
Headache
6.9%
2/29
Gastrointestinal disorders
Nausea
6.9%
2/29
Nervous system disorders
Hand-foot syndrome
6.9%
2/29
Gastrointestinal disorders
Gastritis
6.9%
2/29
Blood and lymphatic system disorders
Granulocytopenia
6.9%
2/29
General disorders
Weakness
6.9%
2/29
Metabolism and nutrition disorders
Hypophosphatemia
6.9%
2/29
Cardiac disorders
Cardiac toxicity
6.9%
2/29
Metabolism and nutrition disorders
Weight loss
6.9%
2/29
Investigations
High creatinine
6.9%
2/29
Musculoskeletal and connective tissue disorders
Myalgia
6.9%
2/29
Nervous system disorders
Neuropathy
6.9%
2/29
Gastrointestinal disorders
Aphagia
6.9%
2/29
Infections and infestations
Afebrile infection
3.4%
1/29
Renal and urinary disorders
Dysuria
3.4%
1/29
Infections and infestations
Axillary necrotic tissue infection
3.4%
1/29
Gastrointestinal disorders
Anal fistula
3.4%
1/29
Blood and lymphatic system disorders
Angioneurotic edema (lymphatic)
3.4%
1/29
Skin and subcutaneous tissue disorders
Leg ambustion
3.4%
1/29
General disorders
Dizziness
3.4%
1/29
Investigations
Bilirubin (hyperbilirubinemia)
3.4%
1/29
Gastrointestinal disorders
Gingival bleeding
3.4%
1/29
Musculoskeletal and connective tissue disorders
Numbness at knee
3.4%
1/29
Blood and lymphatic system disorders
Extravasation changes
3.4%
1/29
Infections and infestations
Infection
3.4%
1/29
Skin and subcutaneous tissue disorders
Erythema multiforme
3.4%
1/29
Blood and lymphatic system disorders
Febrile neutropenia
3.4%
1/29
Investigations
High gamma-glutamyl transferase
3.4%
1/29
Infections and infestations
Influenza
3.4%
1/29
Gastrointestinal disorders
Dyspepsia
3.4%
1/29
Metabolism and nutrition disorders
Hypercalcemia
6.9%
2/29
Metabolism and nutrition disorders
Hypokalemia
3.4%
1/29
Metabolism and nutrition disorders
Hypomagnesemia
3.4%
1/29
Renal and urinary disorders
Urinary incontinence
3.4%
1/29
Renal and urinary disorders
Bloody diarrhea
3.4%
1/29
Musculoskeletal and connective tissue disorders
Muscle pain
3.4%
1/29
Skin and subcutaneous tissue disorders
Complicated dermal toxicity
3.4%
1/29
Eye disorders
Conjunctivitis
3.4%
1/29
Skin and subcutaneous tissue disorders
Contact dermatitis
3.4%
1/29
Musculoskeletal and connective tissue disorders
Cramp
3.4%
1/29
General disorders
Chronic fatigue syndrome
3.4%
1/29
Ear and labyrinth disorders
Ear infection
3.4%
1/29
Blood and lymphatic system disorders
Lymphopenia
3.4%
1/29
General disorders
Flix at lession
3.4%
1/29
Gastrointestinal disorders
Meteorism
3.4%
1/29
Gastrointestinal disorders
Stomach ache
3.4%
1/29
Nervous system disorders
Sensorial motor neuropathy
3.4%
1/29
Respiratory, thoracic and mediastinal disorders
Dyspnea
3.4%
1/29
Gastrointestinal disorders
Oral aphtha
3.4%
1/29
Nervous system disorders
Autonomous motor neuropathy
3.4%
1/29
Respiratory, thoracic and mediastinal disorders
Cough
3.4%
1/29
Nervous system disorders
Peripheral neuropathy
3.4%
1/29
Skin and subcutaneous tissue disorders
Alopecia
3.4%
1/29
Infections and infestations
Common cold
3.4%
1/29
Blood and lymphatic system disorders
Left axillary necrotic fm tissue excision
3.4%
1/29
Blood and lymphatic system disorders
Subdavien venous port implantation
3.4%
1/29
Blood and lymphatic system disorders
Thrombocytosis
3.4%
1/29
Psychiatric disorders
Insomnia
3.4%
1/29
Nervous system disorders
Vertigo
3.4%
1/29
Infections and infestations
Zoster
3.4%
1/29

Additional Information

GSK Response Center

GlaxoSmithKline

Phone: 866-435-7343

Results disclosure agreements

  • Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
  • Publication restrictions are in place

Restriction type: OTHER